About GBN

The "RESOLVE" project (Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across Europe) is being carried out by Martin Luther University Halle-Wittenberg in cooperation with 21 institutions from eight European countries and started on 1 April 2024. The aim is to establish a "gold standard" in the treatment of acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL).   

AML and CLL are among the most common forms of blood cancer in adults. Depending on the stage of the disease, patients receive chemotherapy, immunotherapy or a stem cell transplant. The so-called measurable residual disease (MRD) can be used early on in the course of treatment to determine whether the leukaemia is responding very well to the therapy. It is present when very sensitive measurement methods such as flow cytometry still detect leukaemia cells in the body that cannot be detected with a light microscope. Although MRD has a high predictive value for further treatment, it has not yet been sufficiently scientifically tested to serve as a binding guideline for an individual treatment recommendation. This is now to be clarified by the RESOLVE research network in collaboration with existing expert networks and partnerships with patient involvement. The German Biobank Node (GBN) is involved in the project in an advisory capacity and is contributing its experience in the development of an IT platform.

RESOLVE is part of the "EU Mission on Cancer" funding line, has a duration of five years and a funding volume of eight million euros. GBN receives 50,000 € of this.